European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologicals for felidae, - cats - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs.onsets of immunity isone week after primary vaccination course.the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals for felidae, - cats - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs.onsets of immunity have been demonstrated one week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components.the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals for felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease.onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologicals for felidae, - cats - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs.onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

European Union - English - EMA (European Medicines Agency)

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - immunologicals for felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs.onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus and chlamydophila felis components.the duration of immunity is 1 year after the last (re-)vaccination.

European Union - English - EMA (European Medicines Agency)

virbac s.a. - purified p45 feline leukaemia virus envelope antigen, live feline calicivirus (strain f9), live feline viral rhinotracheitis virus (strain f2), live feline panleucopenia virus - live feline panleucopenia virus / parvovirus + live feline rhinotracheitis virus + live feline calicivirus + inactivated feline leukaemia virus - cats - for active immunisation of cats from eight weeks of age against:feline calicivirosis to reduce clinical signs.feline viral rhinotracheitis to reduce clinical signs and viral excretion.feline panleucopenia to prevent leucopenia and to reduce clinical signs.feline leukaemia to prevent persistent viraemia and clinical signs of the related disease.onset of immunity: 3 weeks after the primary vaccination for the panleucopenia and leukaemia components, and 4 weeks after the primary vaccination for the calicivirus and rhinotracheitis virus components.duration of immunity: one year after the primary vaccination for all components.

Philippines - English - FDA (Food And Drug Administration)

msd animal health (phils.), inc.; distributor: msd animal health (phils.), inc. - live attenuated feline calicivirus (fcv) , feline viral rhinotracheitis virus (fvr) , feline panleukopenia virus (fpl) vaccine (vet.) - suspension for injection (sc) - formulation: each dose contains: feline calicivirus (f9 strain) .....>4.6 log10 pfu feline viral rhinotracheitis virus (g2620a strain) ................>5.2 log10 pfu feline panleucopenia virus (mw-1 strain) .............>4.3 log10 tcid pfu-plaque forming unit tcid-tissue culture infective dose

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals for felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease.onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

United Kingdom - English - VMD (Veterinary Medicines Directorate)

boehringer ingelheim vetmedica gmbh - feline calicivirus, feline viral rhinotracheitis virus - powder and solvent for suspension for injection - live and inactivated viral vaccine - cats

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - feline panleucopenia; feline calicivirus; feline rhinotracheitis - misc. vaccines or anti sera - feline panleucopenia vaccine active 0.0 tci50/ml; feline calicivirus vaccine-viral active 0.0 tci50/ml; feline rhinotracheitis vaccine-viral active 0.0 tci50/ml - immunotherapy